Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have been extended to include treatment of severe active Crohn's disease in children aged 6 years and older.

In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis  | SCIENCE PHOTO LIBRARY
In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis | SCIENCE PHOTO LIBRARY

Humira (adalimumab) can be prescribed in children who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

Dosing recommendations

Children weighing less than 40kg should receive an initial dose of 40mg followed by a 20mg dose two weeks later. Dosing should then be continued at 20mg on alternate weeks, increasing to 20mg once weekly if necessary. In children weighing 40kg or more the recommended dose is 80mg initially followed by 40mg two weeks later, then 40mg every one or two weeks. Humira is given by subcutaneous injection.

View Humira record

Further information: AbbVie Ltd

Follow MIMS on Twitter


Read these next

Humira now licensed for psoriasis treatment in children

Humira now licensed for psoriasis treatment in children

Humira (adalimumab) is now licensed for the treatment...

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

Takeda has launched Entyvio (vedolizumab) for the treatment...

Further licence extension for adalimumab in arthritis

Further licence extension for adalimumab in arthritis

Humira is the first biologic specifically licensed...

Humira approved for use in moderate Crohn's disease

Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have...

Humira: new treatment option for ulcerative colitis

Humira: new treatment option for ulcerative colitis

Humira (adalimumab) can now be prescribed for the treatment...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.